People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer’s disease.

Condition	Treatment or Intervention	Phase
Multiple Sclerosis	Drug: donepezil  Drug: glucose	Phase III

Cognitive dysfunction is one of the leading causes of disability in people with MS. Memory involving specific words (verbal memory) is particularly affected in individuals with MS. Attempts to rehabilitate cognitive dysfunction in MS have had only limited success.

This study will determine the efficacy of donepezil therapy and glucose administration for enhancing verbal memory functioning in individuals with MS. The study will also measure secondary outcomes assessing other areas of cognitive dysfunction (i.e., nonverbal memory, conceptual thinking, processing speed) which may improve with intervention.

Forty participants with MS will be randomly assigned to receive either donepezil or placebo for 24 weeks. Participants will complete memory and cognitive tests at the beginning and end of the 24 week period.

Twenty participants with MS will be randomly assigned to drink a beverage sweetened with either glucose or saccharin (placebo). Participants will then complete memory and other cognitive tests. Two weeks later, participants will drink a beverage sweetened with the alternative sweetener and again complete the memory and cognitive tests.

Ages Eligible for Study:  18 Years   -   56 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

• MS as defined by the Poser criteria
• Expanded Disability Status Scale (EDSS) score of 0 to 6.5
• Stable neurologic function for at least 30 days prior to study entry
• Agree to continue all current medications for study duration
• Rey Auditory Verbal Learning Test score in low normal range or below
• Mini-mental status exam score of 26 or higher
• Montgomery-Asberg Depression Scale scaled score of 14 or lower
• Fluent in English

Exclusion Criteria

• Use of anticholinergic or benzodiazepine medication
• Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry
• Current alcohol or substance abuse
• History of neurological or major medical problem that has a known effect on cognitive functioning
• History of noncompliance
• Visual or upper extremity impairment which precludes ability to participate in cognitive assessment

Patricia Melville, RN      631-444-8164    Pmelvill@neuro.som.sunysb.edu

New York
      University Hospital and Medical Center, Stony Brook,  New York,  11794-8121,  United States; Recruiting

Study chairs or principal investigators

Lauren B. Krupp, MD,  Principal Investigator,  Department of Neurology, University Hospital Medical Center   

Study ID Numbers:  1R01 HD38107-01
Record last reviewed:  December 2003
Record first received:  June 18, 2003
ClinicalTrials.gov Identifier:  NCT00062972
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-10